Germany's Merck to buy Bio-Techne for $73 per share

Bio-Techne Corporation
Merck & Co., Inc.

Bio-Techne Corporation

TECH

0.00

Merck & Co., Inc.

MRK

0.00

June 25 (Reuters) - Merck KGaA MRCG.DE has agreed to acquire biotech firm Bio-Techne Corp TECH.O for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.

The offer price, representing a total enterprise value of around $11.3 billion, represents a 36% premium on Bio-Techne's one-month volume weighted average share price, Merck said.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.